Navigation Links
Charles Drew cancer studies with yeast yield excellent results
Date:2/2/2010

Los Angeles, CAA researcher at Charles Drew University of Medicine and Science is investigating the potential use of non-pathogenic baker's yeast as a promising, natural therapy for cancer.

Dr. Mamdooh Ghoneum presented his findings Tuesday, Feb. 2 at a special conference on "Cell Death Mechanism," sponsored by the American Association for Cancer Research (AACR) at the Omni San Diego Hotel in San Diego.

"The central focus of the meeting is cell death regulation and how to mine and exploit it for therapeutic gain," a written evaluation of the AACR special conference states. "This conference includes new complexities of cell death and cell survival, new technologies, and clinical translational aspects necessary for the evolution of new therapeutic strategies."

For more than two decades, Dr. Ghoneum has pursued a theory that cancer cells self destruct when exposed to small quantities of yeast.

In laboratory tests, Dr. Ghoneum exposed cancer cells to yeast and observed as they ingested the yeastthrough a process known as phagocytosisand then the cancer cells died. First, he investigated this phenomenon in test tubes (in vitro), introducing yeast to breast, tongue, colon, and skin cancers.

"I have no doubt that I am close to unlocking the mystery as to why cancer cells weaken to the point of destruction after eating common baker's yeast," Dr. Ghoneum said. "The cells just gravitate to the yeast. I call it fatal attraction."

In later experiments, yeast was injected inside the tumors of mice and, again, he observed a decrease in the size of the tumor mass. Then, in his most recent tests, he examined whether yeast could kill cancer cells in mice that had cancer metastasized to the lung. These tests also showed significant clearance of the cancer cells from the lung.

"We observed that when the cancer cells eat the yeast, they die," Dr. Ghoneum said.

The next step, Dr. Ghoneum said, is to conduct clinical trials to determine safety, efficacy of dosage and a method of treatment.

Born in Egypt, Dr. Ghoneum earned his Ph.D. at the University of Tokyo in 1980 and did his postdoctoral studies at UCLA, School of Medicine. Dr. Ghoneum is an internationally recognized immunologist, who is an expert in Cancer Immune Therapy. He holds patents for inventing three biological response modifiers for the treatment of cancer. He has been a researcher and professor at Charles Drew University for twenty-five years, specializing in identifying natural cures for cancer.

Dr. Ghoneum's work has been studied and duplicated by leading scientists worldwide with results published in top medical journals. His findings have been confirmed by similar studies at the U.S. Department of Health and Science, National Institute of Health (NIH).

"There is a possibility that we could find a way to treat not only the local tumor, but the tumor that has spread throughout the body," said Dr. Gus Gill, Chairman Emeritus, Department of Otolaryngology, Charles Drew University. "As a surgeon, I always thought that a better way was to try to get rid of surgery (as a necessity) when dealing with cancer."


'/>"/>

Contact: Elia Esparza
eliaesparza@cdrewu.edu
323-563-5822
Charles Drew University of Medicine and Science
Source:Eurekalert  

Related biology news :

1. The surprising story of Charles Darwin and his homeopathic doctor
2. TSC honors Sen. Charles Schumer
3. GEN joins Charles Darwin 2009 celebration
4. Pest management specialist Charles Summers wins prestigious Woodworth Award
5. Why do we choose our mates? Ask Charles Darwin, prof says
6. 2009 Charles River Laboratories Excellence in Refinement Award
7. Charles Darwin really did have advanced ideas about the origin of life
8. Charles Darwin and modern biology
9. Charles Darwin: More than the origin
10. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
11. A study by the MUHC and McGill University opens a new door to understanding cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Charles Drew cancer studies with yeast yield excellent results
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... , ... May 26, 2016 , ... ... company, today announced several positive developments that position the Company for the future. ... of the transaction, Craig F. Kinghorn has been appointed Chairman of the Board, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder ... double board-certified in surgery and surgery of the hand by the National Board ... stranger to going above and beyond in his pursuit of providing the most ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding ... has granted the company’s orphan drug designation request covering BHV-4157 for the treatment ... by the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder ...
(Date:5/23/2016)... ... ... for blood donations in South Texas and across the nation is growing. , But according ... donations are on the decline. In fact, donations across the country are at their lowest ... in the last four years alone. , There is no substitute for blood. , “We ...
Breaking Biology Technology: